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1.   Abstract 
Chronic inflammatory disorders such as Inflammatory Bowel Disease have a 
considerable effect on the metabolism of bone and are generally associated with Bone Mineral 
Disease (BMD) (1). 
In children and adolescents, it is of particular importance because not only does it 
increase the risk of fracture but it has a deleterious effect on overall bone growth, development, 
and peak bone mass (2, 3-4). The mechanisms contributing to bone abnormalities are multifactorial 
however the most important is inflammatory cytokines found in high amounts in inflammatory 
diseases, the use of corticosteroids for treatment of IBD, lack of proper nutritional status and a 
delay in puberty in active disease. All mechanisms are correlated with one another, so there is 
difficulty in pinpointing what the real culprit behind the skeletal abnormalities is. Current 
diagnostic methods consist of several radiating and non-radiating and laboratory techniques, the 
most widely used and available of which is the DXA scan. Measurements from DXA scan are 
correlated to Z-scores that are standardized based on age and gender. With proper z-score 
measurment we can attempt to properly treat children and adolescents with pediatric-onset IBD 
before they reach their peak bone mass. 
Nutritional interventions such as dietary Vitamin D and Calcium supplementation, even 
though are widely used, are not shown yet of substantial efficacy in patients with IBD. With 
understanding the mechanisms of BMD in Ulcerative Colitis and Crohn's Disease, it is crucial to 
focus on the development of targeted therapies that work to maximize growth yet limit disease 
activity in children with IBD. 
Keywords: BMD, IBD, Crohns, Ulcerative Colitis, DXA, Vitamin D, Calcium, Z-score, peak bone mass 
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2.   Sažetak 
Kronični upalni poremećaji, kao što je upalna bolest crijeva, znatno utječu na 
metabolizam kostiju i općenito su povezani s poremećajem mineralizacije kostiju (1) 
U djece i adolescenata to je od osobite važnosti jer ne samo da je povećan rizik od 
prijeloma kostiju, nego je dokazan je negativan učinak na ukupni rast kosti, razvoj i vršnu 
koštanu masu (2, 3-4). Mehanizmi koji pridonose abnormalnom razvoju kostiju su multifaktorni, 
međutim najvažniju ulogu imaju upalni citokini koji se nalaze u velikim količinama kod upalnih 
bolesti, zatim primjena kortikosteroida u liječenju , nedostatak odgovarajućih nutrijenata, i 
kašnjenje puberteta u aktivnoj bolesti . Navedeni mehanizmi su međusobno povezani jedni s 
drugima, stoga je teško odrediti koji je pravi uzrok za abnormalnosti u razvoju kostiju. Trenutne 
dijagnostičke metode uključuju nekoliko radijacijskih i ne-radijacijskih te laboratorijskih tehnika, 
od kojih je najčešće korištena i dostupna DXA denzitometrija. Mjerenja iz DXA skeniranja 
koreliraju se s Z-vrijednostima  koji su standardizirani na temelju dobi i spola. S tim spoznajama 
možemo pokušati pravilno liječiti djecu i adolescente s ranim nastupom upalne bolesti crijeva, 
prije nego što dosegnu svoju vršnu masu kostiju. 
Dodatak vitamina D i kalcija, u prehrani, iako se primjenjuju, nisu za sada pokazali 
značajni učinak u bolesnika s upalnim bolestima crijeva. Uz razumijevanje mehanizma 
mineralne bolesti kostiju kod ulceroznog kolitisa i Crohnove bolesti, ključno je usredotočiti se na 
razvoj ciljanih terapija koje potiču rast, ali istovremeno ograničavaju aktivnost bolesti kod djece 
s upalnim bolestima crijeva. 
Ključne riječi: Poremećaj mineralizacije kostiju,  Upalna bolest crijeva, Ulcerozni kolitisa, Crohnova bolest,  DXA 
denzitometrija, vitamin D, Kalcija, Z-vrijednost, Vršna masa kostiju.  
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3.   Introduction 
Inflammatory Bowel Disease (IBD) is an unyielding, chronic inflammation of primarily 
the digestive tract with characteristic extraintestinal manifestations. IBD can be categorized into 
three subtypes, the most common being Crohn's Disease (CD) and Ulcerative Colitis. The third, 
least common form, localized primarily in the colon, when differentiation is not yet possible, is 
labeled as Unclassified Colitis (IBDU). IBD was described in early medical literature several 
centuries ago as an erratically occurring disease, but it was not until the 19th and early 20th 
century that its attention was gained in the medical community by US physician Crohn and 
British physician respectively. Similar to other diseases, UC and CD have a steady increase in 
their incidence since the early 20th century for UC and the mid and late 20th century for CD. 
  
3.1  Epidemiology 
The disease can occur from as early as childhood but is most commonly diagnosed 
between the ages of 15 to 30 years. Genetic and environmental factors are an explanation for the 
epidemiological differences of IBD in newly industrialized and westernized countries. There is 
also a difference of observations in studies performed in already westernized and newly 
industrialized countries due to increased diagnostic capabilities as shown in the Barnes and 
Kappelmann (7) study on the incidence of Pediatric onset IBD in the north of France. Such 
epidemiological differences can also be seen with two large-scale studies. One retrospective 
cohort study was done in the UK with a follow-up of 6 million person-years linking the use of 
antibiotics and pediatric-onset IBD. Another prospective cohort done on the Danish population 
also linking antibiotics to IBD but this time it was more specifically associated with CD (8,9). 
Although there are many associations of instigating factors that are linked to IBD including 
 4 
 
smoking, hygiene hypothesis, microorganisms of the gut microbiome, appendectomy, 
medication, nutrition and stress, the exact mechanism behind these connections are still not well 
understood. More and more factors are being linked to IBD in the present and future studies and 
possibly one day will be more clearly understood (10). 
  
3.2  Diagnosis and Features of Disease 
There is variation in factors that distinguish the diagnosis of the different types of 
Inflammatory Bowel Disease. Initial evaluation of pediatric patients suspected of IBD consists of 
a series of diagnostic tests which include upper endoscopy, colonoscopy with ileoscopy (with 
biopsies), upper GI series with barium and small bowel follow-through or in older children MR 
enterography, Less commonly there is also serologic testing, capsule endoscopy, and abdominal 
CT. (1) 
The North American Society for Pediatric Gastroenterology, Hepatology and Nutrition 
(NASPGHAN) has set up guidelines based on an algorithm that helps physicians in decreasing 
the variability in diagnoses between Crohn's disease, Ulcerative Colitis and minimizing needing 
to diagnose Indeterminate Colitis. This decrease in diagnosis variability is epidemiologically and 
medically crucial for future research of the disease, and for appropriate treatment in today's 
times. Based on NASPGHAN algorithm, UC and Unclassified Colitis (IBDU) are both diagnoses 
of exclusion from CD. 
Main features used in the diagnosis of CD is made by a thorough physical exam, 
Radiographic imaging, Colonoscopy, and Histology. On physical exam, perianal fistulas and 
abscesses can be found along with skin tags reaching a size of more than 5mm. On imaging one 
can see that there is definitive small bowel involvement. With colonoscopy, the classic linear 
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ulceration, cobblestone appearance, and ileocecal stenosis are found, as well as strictures and 
fistulas. Histologically CD consists of non-caseating granulomas in 25-61% of patients and with 
colectomy one can find transmural lymphoid aggregates (11). 
Though the above criteria are diagnostic of CD, patients without these features should 
also be suspected of CD when having growth failure, an abdominal mass, discontinuous 
intestinal inflammation (as opposed to continuous lesions found in UC), or aphthous ulcers.  
 
Figure 1 Differentiation between UC and CD and IBDU 
NASPGHAN guidelines for differentiating diagnosis between UC, CD and IBDU, Modified (12).  
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When a patient has such suggestive features of CD but no diagnostic features, the 
diagnosis should primarily be put as IC and patients should be followed up until a more 
definitive diagnosis can be made. On the other side, we have UC which has its typical features of 
continuous diffuse inflammation that starts most commonly presents as pan colitis or left-sided 
colitis,  or moves more proximally in the colon while sparing the rectum. 
Serum antibodies can be tested for both Crohn's Disease and Ulcerative Colitis, ASCA, 
and P-ANCA respectively, but are not strongly associated and their Positive Predictive Values 
(PPV) are dependent on the level of symptoms. Patients who have an increased prior likelihood 
of having the disease will have less false positives than those lacking characteristic symptoms. 
There is also another serologic marker, anti-OmpC antibody, which is not specific to either CD 
or UC. However, it was found to be positive in some children with IBD which were not detected 
by other markers. The addition of this marker would increase sensitivity from 63% to 70%, as 
well as decrease the specificity from 97% to 94% (13). It is also necessary to look at inflammatory 
lab parameters such as Erythrocyte Sedimentation (ESR), C-reactive Protein (CRP), fibrinogen 
which would be elevated in active disease, and in CD levels of albumin and total albumin-
globulin protein ratio which would be low. 
  
3.3     Extraintestinal  Manifestations 
Although the gastrointestinal tract is the primary system affected by both CD and UC, 
multisystem involvement is possible as well. The prevalence of the presence of extraintestinal 
manifestations (EIM) of both conditions is not clearly outlined and is varying widely from author 
to author. Even so, there seems to be a combined finding that a higher number of pediatric 
patients versus adult patients develop more than just intestinal involvement. Extraintestinal 
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symptoms may appear before intestinal symptoms, synonymously with them or may develop 
later in the disease. For pediatric-onset IBD, the most striking feature would be growth 
retardation or cessation and lack of sexual development. Extraintestinal manifestations can 
commonly be seen in the oral cavity, liver, skin, joints and bones, blood, and eye. Such examples 
include arthritis,arthralgias, and spondyloarthropathies, erythema nodosum, aphthous stomatitis, 
episcleritis/uveitis and many less common ones. Other body systems can as well be affected but 
it is rare. 
 Inevitably with the chronicity of UC, CD, and IC in children, the toll it takes is on 
childhood development. The manifestation which will be the focus of this review will be bone 
mineralization disorder, of which the etiology is multifactorial yet still a direct consequence of 
all three forms of pediatric-onset IBD. 
  
3.4   Treatment 
Treatment of IBD is based on pharmacological, nutritional and/or surgical. Regarding 
pharmacological treatment, corticosteroids play still an important role in flare-ups and are 
important in inducing remission in a patient with active IBD. A good solution for avoiding 
steroid side effects is use of enteral nutrition. There is the same remission induction rate as with 
steroids alone and is mostly effective in mild or moderate nonfistulising Crohn's disease. For 
maintenance therapy, it is recommended to introduce immunomodulators such as azathioprine 
(AZA), a purine analog, for both CB and UC  or methotrexate for CB,  Biologic therapy,  
infliximab or adalimumab, the monoclonal antibodies that block TNFα, are recommended in 
severe cases. In pediatric patients, one of the main challenges is reducing the severity of 
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intestinal inflammation in order to optimize growth and pubertal development which will be 
further discussed later (14). 
  
4.0      Pathophysiology of Bone Formation and Mineralization 
The human skeleton, especially in the adolescent age, is a dynamic and influential organ 
that is continuously regenerating, growing and changing. Bone is important both structurally and 
metabolically. Metabolically, bones manage and store large amounts of calcium, carbonate, and 
phosphorus, and can control and buffer changes in hydrogen concentrations. Structurally, bone is 
crucial for mobility, respiration, and protection of internal organs and also the hematopoietic and 
immunologic cell's system (15). 
 During childhood growth and development, the skeleton goes through the process of 
modeling itself by depositing bone from one place to another until it reaches its maturity and 
ideal shape and size. Once the skeleton has reached its peak bone mass, modeling is replaced 
with the process of remodeling where there is a replacement of old bone with new, this process is 
done by specialized cells that make up the Bone Multicellular Unit (BMU). A BMU consists of 
osteoclasts, osteoblasts behind them, a blood supply, and connective tissue. In this order, there is 
first resorption of old bone by osteoclasts and the formation of new bone by osteoblasts (16).  The 
result of a wholly remodeled cycle is the formation of an osteon. The function is not only for 
maintenance of the mechanical competence of bone but also to keep homeostasis for minerals in 
the body by mobilizing and storing calcium, magnesium and phosphorous. There is excellent 
coordination between the skeleton and intestines, the major contributor of ionic absorption, 
therefore, dysregulation of intestines can affect bones and bone development significantly.  The 
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difference in the amount of bone removed and formed is called a bone balance, and this varies 
with gender, age and diseased versus healthy states (17-19). 
Many regulators interact together for the processes of bone formation and mineralization, 
which are mainly divided into ones with systemic effects and ones which have both systemic and 
local or mainly/solely local effects on bone. The primary systemic regulators include parathyroid 
hormone (PTH), Vitamin D, Calcitonin, Estrogens, Androgens, Growth Hormone (GH)/ Insulin-
like Growth Factor 1 (IGF-1), Thyroid Hormones, and Steroids. Other factors include cytokines, 
leukotrienes, nitric oxide (NO) prostaglandins and TNFα each promoting mainly resorption but 
may also be stimulative on the formation. 
  
4.1      Parathyroid Hormone 
PTH is the key regulator of calcium homeostasis. It maintains serum calcium 
concentrations in the blood not only by increasing the amount that is reabsorbed by the renal 
system and increasing calcitriol production by the kidneys. PTH has a stimulatory effect on bone 
formation when it is released or given intermittently. Consequently, it impedes on the production 
of collagen higher concentrations (20). Although PTH does stimulate bone formation, when it is 
given or secreted in a continuous flow it also has a bone resorptive effect in a process that is 
mediated by osteoclasts (21,22). PTH also increases the production of several local factors, 
including interleukin (IL)-6, IGF-1, and IGF-binding protein (IGFBP-5), and prostaglandins. 
  
4.2      Vitamin D          
The active Vitamin D metabolite 1,25(OH)2D mainly stimulates the gut to absorb 
calcium and phosphate, creating an optimal condition for mineralization. Therefore 
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insufficiencies lead to secondary hyperparathyroidism, and bone loss which later leads to 
osteomalacia and an increased risk of fractures.  In the gastrointestinal tract, calcium is mostly 
absorbed in the duodenum and proximal jejunum. Depending on the segment and the 
concentration of calcium in the lumen, it is absorbed either through a weakly regulated 
paracellular route or by a highly regulated vitamin D3-sensitive transcellular pathway. Therefore 
if the concentration of calcium is low in the lumen, Vitamin D is needed to regulate and increase 
absorption of the calcium that is in the lumen to maintain sufficient levels (23). 
As stated above continuously increased PTH (which is the case in hyperparathyroidism) 
is unfavorable due to its stimulatory effect on the bone turnover rate which is carried out by the 
BMU. An increased bone-turnover rate leaves more osteoid type bone or unmineralized bone 
which is undesirable, especially in a growing child (24). In contrast to Vit D, calcitonin inhibits 
osteoclast activity, reducing bone resorption. A body in homeostasis with the appropriate amount 
of actions of vitamin D and calcitonin results in a positive bone balance (25). 
  
4.3      Estrogens and Androgens 
In children that are going through puberty, sex hormones are critical in shaping the bone 
structure. (1) Increases of these hormones during puberty decrease resorption of bone and limit 
bone remodeling. Androgens act directly on receptors, found on the epiphyseal plates, to 
stimulate bone formation. Indirectly they stimulate muscle formation which gives bones 
incentive to grow and mineralize (26,27). Estrogens are responsible for the maturation and 
mineralization of bone. Indirectly, estrogens work on receptor activator of nuclear factor kappa-
Β ligands (RANKL), by inhibiting it, through the action of osteoprotegerin, a decoy receptor of 
the RANKL. RANKL is a cytokine that is secreted by osteoblasts and T cells which interacts 
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with the receptor activator of nuclear factor-κB (RANK), found on the membrane of osteoclasts, 
where it activates bone resorption (28). RANKL inhibition decreases differentiation and activation 
of osteoclasts. Therefore, deficiencies in estrogen and androgen cause bone loss due to an 
increased rate of bone remodeling and the imbalanced osteoclast and osteoblast proliferation 
ratio (29,30). 
  
4.4      Growth Hormone and IGF-1 
Growth hormone is a peptide hormone with essential effects on bone growth such as the 
proliferation of pre-chondrocytes, remodeling and formation of bone, and increasing net 
mineralization (31). Children that are deficient are faced with a failure to grow, short stature and 
delay of sexual maturity which all contribute to a lower peak bone mass and bone mineral 
disease. The relationship between IGF-1 and GH is abstruse, however, simply put, GH stimulates 
the gene transcription and secretion of IGF-1 by the liver and indirectly stimulates IGF-1 through 
the action of chondrocytes and osteoblasts. GH is a principal determinant of IGF-1 and IGF-1 is 
the mediator of most actions of GH (32). 
  
4.5      Thyroid Hormone 
Increased amounts of circulating thyroid hormone are associated with increased bone 
remodeling (resorption and formation) which leads to a lower BMD. Thyroid hormones may act 
on bone cells either indirectly by increasing secretion of growth hormone (GH) and insulin-like 
growth factor-1 (IGF-1), or directly by influencing target genes via specific nuclear receptors. It 
is thought that thyroid hormone may work indirectly on bone cells by activating secretion of 
growth hormone and insulin-like growth factor-1 or by directly influencing osteoblasts and 
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osteoclasts through the specialized receptor, thyroid receptor-alpha-1 (TR alpha-1) that is found 
in bone cells (33.). There is also significance in the increased levels of interleukin-6 (IL-6) found 
in patients with hyperthyroidism in which IL-6 acts excessively on osteoclast production by 
stimulating it, thus causing a lower BMD (34). 
  
4.6      Corticosteroids 
Steroids play a vital role in the resorption and formation of bone especially in children 
that are being treated with IBD flare-ups or treatment of initial flare-up with steroids. 
Corticosteroids cause bone loss by inhibiting formation, increasing resorption, decreasing the 
intestinal absorption of calcium, and increasing excretion of calcium through the kidney. This 
topic will be discussed in more detail later on with the pathogenesis of Glucocorticoid therapy. 
  
4.7      Peak Bone Mass 
Peak bone mass is defined as the amount of bone mass that is developed at the point in 
time in which skeletal maturity is reached. There is no definitive age in which normal peak bone 
mass is achieved, but it is mostly seen in late adolescence within the second decade of life (18). 
Throughout childhood, bone growth is linear and does not significantly differ between genders 
until the onset of puberty at which there is an acceleration in bone mass that accounts for more 
than 40% of the total adult bone mass and the differences of bone in boys and girls starts to 
differ. 
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5.0      Pathogenesis of BMD in children with IBD 
In the population of pediatric patients suffering from IBD whether it be CD, UC, or IC, 
there are certain risk factors specific for this group that make them more susceptible in 
developing BMD. Malabsorption, Glucocorticoid Therapy, Chronic Inflammation due to the 
disease activity, and Hypogonadism all play a role in making children with IBD vulnerable to 
BMD. To properly assess disease activity in children and adolescents for both CD and UC there 
are Standardized Assessment Tools, Pediatric Crohn’s Disease Activity Index (PCDAI) and 
Pediatric Ulcerative Colitis Activity Index (PUCAI), respectively, which are used, and based on 
a given numerical score are interpreted. Scores are evaluated by several factors such as 
abdominal pain, number of stools per day, blood in stool, weight, linear growth, lab studies etc.  
and then organized into three to four categories rating the severity of disease. Ranges are from 
inactive disease to mild, moderate and finally severe disease activity (35-39). 
 
3.1   Malabsorption and Nutrient Deficiency 
 Malnutrition is the result of malabsorption, decreased dietary intake, sometimes 
maldigestion, and increased energy expenditure. Particularly apparent in CD, malabsorption of 
lactose and fat-soluble vitamins such as A, D, E and K are common (40). The cause is 
multifactorial, mostly being caused by, in some cases, shortening of the small bowel length, 
giving less surface area for nutrients to be absorbed and possibly bile acid deficiency from 
terminal ileum resection; and inflammation of the bowel, making the diffusion of nutrients 
through the bowel much harder. Bacterial overgrowth also plays a role in making nutrient 
absorption more difficult. Since the focus of this review is BMD, focus will be put on Vitamin D 
deficiency. As previously mentioned, a decrease in the active metabolite of vitamin D, 
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1,35(OH)2D leads to consequences like a decrease in calcium absorption from the intestines 
which in turn leads to bone loss and increase of bone-turnover due to activation of PTH.  With an 
increase in bone turnover there is more remodeling of the surface of the bone and there is less 
mineralization due to the fact that the age of osteon is younger and mineral accumulation takes 
time after formation. With chronic malabsorption, leading to chronic vitamin D deficiency, the 
amount of unmineralized osteoid tissue can accumulate to more than 5% (14). It was shown in a 
study that deficiency in vitamin D is very common in IBD, about 65% of CD patients had low 
serum calcidiol (25-hydroxyvitamin D levels, most probably due to their increased risk of bowel 
segment removal surgeries and lactose intolerance which is more likely to keep them away from 
dairy products, an established source of calcium and Vitamin D (41,42).The cause of insufficient 
vitamin D is also multifactorial and can be attributed to genetic factors or lack of sun exposure. 
 
5.2      Glucocorticoid Therapy 
Corticosteroids regulate a diverse array of physiological processes and are used in the 
treatment of several inflammatory diseases. It is more prevalent in patients with IBD that are 
treated with corticosteroids to have bone loss (43). They have a well known detrimental effect on 
bone and growth. It was first described by Cushing in 1931 and later in 1992 was demonstrated 
in rabbits the direct inhibitory effect dexamethasone had on the growth plate when it was given 
directly into the epiphyseal plate (44,45). In treatment with steroids, the time at which the risk of 
bone loss is most prominent is in the first few months of use. Continued use showed that there 
was a steady decrease in overall bone mass (46.). It was shown that particularly with high dose 
steroids, there was not only a decrease in the production of osteoblasts but also an increase in the 
apoptosis of osteoblasts and osteocytes (47). Osteoclast proliferation is stimulated by steroids 
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5.3   Inflammatory Cytokines 
The effects of glucocorticoid use versus the effects of inflammatory activity due to 
chronic disease are hard to differentiate (51). It is, however, apparent that the mechanism of BMD 
in IBD is similar to other chronic systemic inflammatory diseases such as Rheumatoid Arthritis 
(RA) or Systemic Lupus Erythematosus (SLE) (52). BMD is found in patients without any other 
factor to be accountable and this is exemplified by observations such as mild cortical bone loss 
found in children who are newly diagnosed and on histomorphometric analysis of subjects with 
clinically dormant IBD (more precisely CD) were also found to have low BMD and a decrease in 
mineral apposition rate (53-56). Although the mechanism of low BMD is not well understood, there 
is a possibility that the chronic inflammation leads to excessive production of cytokines, such as 
RANK (through dual action by osteoprotegerin) and IL-6, IL-1β, TNFα (Tumor Necrosis Factor 
alpha). Osteoprotegerin, the decoy receptor of RANKL, is secreted by osteoblasts along with 
RANKL and it was shown to be elevated in the plasma in patients with CD and UC, compared to 
controls, unlike RANKL which was not very different from control subjects (57).  An increase of 
these cytokines causes resorption of bone without any compensatory increase in the formation of 
new bone (51, 58, 59). IL-6, IL-1β, TNFα are shown to be elevated in chronic inflammatory states 
like IBD and are involved in osteoclast-mediated bone resorption through the action of the p38 
mitogen-activated protein kinase (MAPK) pathway  (60). High concentration of IL-1β are found in 
both CD and UC, and it is a key mediator of bone resorption through the action of RANKL, 
which promotes the production of osteoclasts. IL-6 is also significantly increased in monocytes 
in patients with IBD, and there is a significant reduction in osteoclast formation and bone erosion 
with blockade of IL-6 (61).  Evidence supporting the action of cytokines can be seen through 
pharmacological studies done which worked on the blockade of said cytokines such as IL-6 and 
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TNFα. Tocilizumab, a humanized antibody that blocks IL-6, has shown promise in inflammatory 
arthritis patients in reducing systemic bone resorption (62).  Miheller et al. also demonstrated that 
in patients treated with infliximab (an inhibitor of TNFα) there was a decrease in the 
osteoprotegerin levels, improvement in BMD status and a higher BMAD (63). Based on the role 
RANKL has on bone resorption, there is a chance that a monoclonal antibody, denosumab, can 
one day be an effective therapy in the prevention and treatment of BMD in children with IBD (64). 
 
5.4   Hypogonadism and Decrease in Sex hormones 
Hypogonadism and pubertal delay are common in the pediatric population that has active 
IBD. A consequence of this is a decrease in linear growth, lack of lean muscle accumulation and 
delay of bone age which can affect peak bone mass during adolescence. Malnutrition, 
inflammatory processes and use of corticosteroids in the treatment of IBD all contribute to the 
hypogonadism in children (65). Inflammatory cytokines directly inhibit gonadal sex hormone 
production and the deficiency in body mass (which can be assessed by leptin levels which are 
equivalent to body fat) found in many IBD patients is preventing the onset of puberty by 
disrupting pituitary-gonadal function and activation of the gonadotropin-releasing hormone (66). 
  
6.0      Diagnosis and Assessment of BMD 
The World Health Organization (WHO) classification of BMD should not be used when 
assessing children and adolescents according to the International Society for Clinical 
Densitometry (ISCD) (67). In the pediatric group, Z-scores (instead of T-scores) are used to 
interpret DXA scans. This is due to the fact that it is not pertinent to compare an adolescent or 
child who has not reached peak bone mass with an adult who already has. Densitometric criteria 
alone are not enough for diagnosis of osteoporosis. There must be an apparent history of fracture 
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and low Bone Mineral Content (BMC). A clinically significant fracture history must contain at 
least one of three incidences:  fracture of a long bone of the lower extremity, vertebral 
compression fracture, and/or two or more fractures of a long bone in the upper extremity. BMD 
or low BMC is defined as a Z-score (that is adjusted for body size, age, and gender) less than or 
equal to -2.0 and the term osteopenia should not be used in the pediatric population (68). Precise 
BMD measurement is difficult in the pediatric population due to confounders one of which is the 
lack of a standardized reference database for Z-scores (69). DXA scan is the most widely used tool 
in measuring BMC. There are however other methods such as Peripheral Quantitative Computed 
Tomography ( pQCT), Quantitative ultrasound (QUS) and Biochemical markers to screen for 
BMD. 
  
6.1   DXA scan and Z-score 
Beginning in the 1980s, DXA scan has become the most accessible, non-invasive clinical 
procedure for investigating BMD. In adult medicine, for people suffering from osteopenia and 
osteoporosis, DXA scan is the gold standard for diagnosis (70). The growing concern for bone 
health in children has made its use increase rapidly as well in the pediatric population, and has 
become a widely available bone densitometry technique for bone status measurements in 
children (71). DXA scan BMC measurements of the lumbar spine (as oppose to hip) is the most 
widely used technique in assessment of BMD in the pediatric population.  
 DXA is a two-dimensional technique that uses x-ray transmission through the body at 
both high and low energy levels (72). The reason for both energy levels is because they are each 
attenuated differently, and thus information about soft tissue and bone is achievable along with 
the ability to distinguish between the two. DXA scan pixels measure the areal BMD (aBMD) 
which is expressed in g/cm3. The BMC is calculated by multiplying the Bone area (BA) by the 
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measure aBMD. The absolute value is then expressed as either a T-score or Z-score, in this case, 
for children, it is Z-score (73). A Z-score is a comparison of bone density to the average for one's 
gender and age, whereas a T-score reports the difference in bone mass of an average 30-year-old 
male. When BMC Z-scores are between -1.0 and -1.9 they are suggested to be classified as an “at 
risk for low bone mineral density or bone mineral content for chronologic age” group. When 
BMC Z-scores are less than or equal to -2.0, “low bone mineral density or bone mineral content 
for chronologic age” is suggested (74). Diagnosis of osteoporosis is made with a Z-score of -2.0 
and a history of fracture that falls under the three previously mentioned categories. 
 Advantages of using DXA are rapid scan times, the availability of reference data in the 
pediatric population and cost is inexpensive. DXA scan can be used to measure the whole body 
or particular regions of interest, especially lumbar spine, and it is currently the only technique 
used in the measurement of hip region BMD in children (75). 
  
6.2   QCT and vBMD 
Quantitative Computed Tomography(QCT) consists of axial QCT (spine) and peripheral 
QCT (pQCT; radius, tibia, femur). These methods became regularly used during the 1980's 
before the DXA scan was popularized. QCT results are presented as the mean volumetric BMD 
(vBMD) and expressed as mg/cm3. When measuring the trabecular vBMD, which is one of the 
advantages QCT has over DXA scan, the result is an amalgamation of the bone and the marrow 
per voxel which may confound the measurements in adults. However, in children, bone marrow 
fat is limited. Therefore, vBMD results are more precise. The limitations of axial QCT such as a 
several-fold increase in the dose of ionizing radiation, lack of accessibility to equipment and 
analysis software, and the need for skilled technical staff has prevented it from developing 
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6.4   Laboratory Evaluation 
There are several markers connected to bone formation and resorption that can be 
identified in daily practice. Markers for osteoblast activity, such as osteocalcin and bone alkaline 
phosphatase (ALP), osteoclast activity such as tartrate-resistant acid phosphatase, and other 
breakdown products can be used. There have been investigations into these markers in screening 
for BMD in IBD but have been of limited use in the clinical setting (80-82). Bone sensitive ALP in 
high concentrations has been considered a reliable biomarker to predict bone mineral status and 
as an indicator to continue with radiological diagnostics (83). In patients already found to have 
low BMC, laboratory diagnostic tests can help distinguish possible other causes of bone loss 
such as hyperparathyroidism, Vitamin D deficiency , renal disease or liver disease. As a general 
rule, necessary tests that should be ordered are a Biochemistry profile (Ca2+, phosphorus, 
albumin and total proteins, creatinine, liver function tests (LFTs), and electrolytes), 25(OH) Vit 
D levels, complete blood count (CBC) and Testosterone for males. 
  
7.0      Treatment and Follow up of BMD in children with IBD  
According to the NASPGHAN, there are current recommendations regarding the 
monitoring and stabilizing bone health in adolescents and children suffering from UC, CD or IC. 
Clinicians should obtain consistent follow-up measurements of BMD every one to two years in 
patients with pediatric-onset IBD who have a total body (minus head and spine) Z-score of less 
than -1.0 (76). There is not much data on the prevention and treatment of low BMC in patients 
with IBD especially data that is specifically for the pediatric population. Based on the 2017 
American College of Rheumatology guidelines for steroid induced prevention of osteoporosis, 
nutritional interventions such as dietary Vitamin D and Calcium supplementation are widely 
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used in patients treated with steroids and patients that are seen to have low z-scores, even though 
there is not much evidence proving its efficacy (84). The overview of maintenance of bone health 
includes changes in lifestyle habits (exercise); correction of gonadal steroid hormone and vitamin 
D deficiencies, minimizing the use of glucocorticoid (i.e., changing the dose, type, and duration)  
and pharmacologic therapy if all else fails (85-89). When it comes to pharmacologic therapy, there 
is a minimal connection that the use of biologics has favorable outcomes concerning bone health 
and there are no current recommendations for these solely to control low BMC in children. Oral 
bisphosphonates have been found to be effective in improving bone mineralization status of 
children with significant morbidity from their compromised bone health (90). Again, there is little 
evidence and research that accurately examines specifically the treatment of BMD in pediatric-
onset IBD. 
 
8.      Discussion 
 1964 was when the first connection between IBD and BMD was proposed, by Edwards 
and Truelove, after which came several studies concluding that low BMC is a common problem 
in children and adolescents suffering from IBD (2, 3-4).  
It is of great importance to understand the mechanism of BMD specifically for children in 
IBD to shorten the time till diagnosis, to maximize efficacy of the treatment and to overall 
improve the treatment options in children. Unfortunately there are not many choices for pediatric 
patients in this disease, therefore there is not much individualization in treatment of it. 
Understanding the reason behind the low BMC, whether it be inflammation based or from 
treatment of flare-ups with steroids, we can develop and learn to use more efficient drugs that are 
targeting key regulators in bone mineralization. Denosumab, a highly specific inhibitor of 
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RANKL, has shown efficacy in the pediatric population to increase bone mineral density with 
minimal side effects, one of which is reduced calcium with increased parathyroid hormone (91). 
However this drug is used very rarely and not at all in most countries for the treatment in IBD. 
The mainstay of therapy for BMD in children is still Vitamin D and Calcium and will continue to 
be until there is enough studies done on a more targeted approach to this condition. Beginning 
there’s studies on the targeting of main culprits, such as with denosumab on RANKL, is a step in 
the right direction for a more individualized approach in treatment of Bone Mineral Disease in 
children with Inflammatory Bowel Disease. 
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